Neoadjuvant PD-1 Antibody Alone or Combined With DC Vaccines for Recurrent Glioblastoma

Inclusion Criteria:

1. Age from 18 to 70 years.
2. Eastern Cooperative Oncology Group (ECOG) performance status of 0,1 or 2.
3. Estimated life expectancy > 3 months.
4. Previous first-line therapy with radiotherapy and chemotherapy, first or secondrelapse with unequivocal evidence of tumor progression.
5. Pathological diagnosis or molecular diagnosis for lesion this time was confirmed to berecurrent brain glioma (WHO grade 4).
6. Patients with subtotal resection or above of the tumor confirmed with contrast MRwithin 72 hours after surgery.
7. No high-dose systemic corticosteroids (defined as >10 mg day-1 of prednisone orbio-equivalent for at least seven consecutive days before administration).
8. No antibiotics for at least three consecutive days before administration.
9. Adequate organ function defined by: Adequate bone marrow reserve: absolute neutrophil (segmented and bands) count (ANC) ≥ 1.0×10^9/L, platelets ≥100×10^9/L; hemoglobin ≥ 8 g/dL. Hepatic: bilirubin 2×upperlimit of normal (ULN), aspartate transaminase (AST) and alanine transaminase (ALT) < 2.5×upper limit of normal (ULN). Renal: Normal serum Creatinine for age (below) orcreatinine clearance >60 ml/min/1.73 m2. Electrocardiogram: normal.
10. Written informed consent.
11. Patient should have good follow-up compliance.

Exclusion Criteria:

1. Pregnant or breast-feeding patients.
2. Patients with uncontrolled intercurrent illness including, but not limited to ongoingor active infection, symptomatic congestive heart failure, unstable angina pectoris,or psychiatric illness/social situations that would limit compliance with studyrequirements.
3. Patients with history of immune system abnormalities such as hyperimmunity (e.g.,autoimmune diseases) and hypoimmunity (e.g., myelodysplastic disorders, marrowfailures, AIDS, ongoing pregnancy, transplant immuno-suppression), or medication ofcortisol.
4. Patients with any conditions that could potentially alter immune function (e.g., AIDS,multiple sclerosis, diabetes, renal failure).
5. Any previous investigational medication within 30 days before first administration ofCamrelizumab.
6. History of allergy to study drug components or of severe hypersensitivity reactions toany monoclonal antibodies.